{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T11:02:57Z","timestamp":1784199777194,"version":"3.55.0"},"reference-count":12,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"vor","delay-in-days":21,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The urothelial carcinoma (UC) trial landscape has expanded over two decades, alongside a shift from chemotherapy to immunotherapy and targeted approaches. We characterized temporal patterns in trial phase, interventions, sponsorship, geographic footprint, and the uptake of biomarker specification and artificial intelligence (AI) terminology.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We conducted a trial registry\u2010based analysis of 823 interventional UC studies first posted on\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/clinicaltrials.gov\">ClinicalTrials.gov<\/jats:ext-link>\n                      during 2005\u20132024. Trials were classified by phase, recruitment status, and intervention, and further stratified by sponsor type and geographic region. Registry text was mined to flag biomarker\u2010specified and AI\u2010enabled registrations. Trends were summarized overall and for two periods: 2005\u20132014 and 2015\u20132024.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Annual registrations increased after 2015, peaking in 2018. Early\u2010phase studies predominated overall, with expansion of Phase 3 activity in 2015\u20132024. Drug interventions remained dominant as immunotherapy displaced chemotherapy; pembrolizumab was the leading agent in the later period. The sponsor mix shifted toward industry, and the geographic footprint broadened: the United States\/Canada remained the largest contributor, with growth in multinational activity and increased participation from East Asia. Biomarker\u2010specified language rose to roughly one quarter of registrations in 2015\u20132024, whereas explicit AI terminology was rare. Early\u2010phase termination rates were notable.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>UC trials have scaled and globalized while consolidating immunotherapy and advancing genomically directed strategies. Priorities include precise preregistration of biomarker and computational endpoints, inclusive multinational accrual, and adequately powered comparative trials against current standards to accelerate durable clinical benefit.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/cam4.71859","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T04:59:17Z","timestamp":1782190757000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Navigating the Evolution of Urothelial Carcinoma Treatment: From Chemotherapy to Immunotherapy"],"prefix":"10.1002","volume":"15","author":[{"given":"Ben","family":"Li","sequence":"first","affiliation":[{"name":"Medical College of Jinzhou Medical University  Jinzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziqi","family":"Yang","sequence":"additional","affiliation":[{"name":"Medical College of Jinzhou Medical University  Jinzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8949-519X","authenticated-orcid":false,"given":"Yihao","family":"Pei","sequence":"additional","affiliation":[{"name":"Medical College of Jinzhou Medical University  Jinzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[{"name":"Medical College of Jinzhou Medical University  Jinzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumin","family":"Chen","sequence":"additional","affiliation":[{"name":"Liaoning University of International Business and Economics  Dalian China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,6,22]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.21037\/tau\u201022\u201043"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1177\/1756287219839285"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz127"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1470\u20102045(17)30065\u20107"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature13904"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140\u20106736(16)00561\u20104"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2002788"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312117"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.03.001"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817323"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2308849"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16040810"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.71859","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cam4.71859","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.71859","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T10:02:55Z","timestamp":1784196175000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.71859"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":12,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1002\/cam4.71859"],"URL":"https:\/\/doi.org\/10.1002\/cam4.71859","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"2025-08-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e71859"}}